We are a clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare diseases and diseases with high unmet need. Since our inception in 2013, we have focused our efforts and financial resources on acquiring and developing product and technology rights, building our intellectual property portfolio and conducting research and development activities for our product candidates.
Partnerships GSK (Sep 2022 exclusive license): IND and NDA ownership transferred to GSK; Spero eligible for milestone payments and royalties on future sales
Indications
Complicated urinary tract infections including pyelonephritis, caused by certain susceptible pathogens in adult patients with limited or no alternative oral treatment options(Approved)
Status note FDA approved on June 17, 2026 following the NDA Class 2 resubmission submitted December 2025.
SP001
Preclinical · ActiveModality: Monoclonal antibody
Target CD40L
Partnerships Innovent Biologics (Suzhou) and Fortvita Biologics (USA) (Jul 8, 2026 license agreement): exclusive worldwide rights (excluding mainland China, Taiwan, Hong Kong and Macau) to research, develop, manufacture and commercialize SP001 for IgG4-related disease
Indications
IgG4-related disease(Preclinical)
Status note Lead program. Company shifted focus and resources to SP001 development following Utebzi approval.
Per-asset detail extracted from the 10-Q filed 2026-08-12. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
No lead program on file for this company.
No active ClinicalTrials.gov trials matched to this company as sponsor or collaborator.
Specialist fund holders
Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.
None of the tracked specialist funds reported a position in the latest 13F snapshot.
Latest news
Loading headlines…
Headlines from the Fully Diluted live wire: IR newsrooms, newswires, SEC filings, and halt notices, refreshed every 15 minutes.
Get the weekly biotech catalyst rundown. Cash runways, financings, and trial readouts for all 721 stocks.